Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Evaluating the Efficacy of Degarelix as Neoadjuvant Androgen-Deprivation Therapy (ADT) followed by Radiation Therapy in Control of Acute Genitourinary Toxicity Associated with Radiation Therapy for Prostate Cancer Compared to Luteinizing Hormone-Releasing Hormone (LHRH) Agonist

Trial Profile

A Study Evaluating the Efficacy of Degarelix as Neoadjuvant Androgen-Deprivation Therapy (ADT) followed by Radiation Therapy in Control of Acute Genitourinary Toxicity Associated with Radiation Therapy for Prostate Cancer Compared to Luteinizing Hormone-Releasing Hormone (LHRH) Agonist

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 May 2018

At a glance

  • Drugs Degarelix (Primary) ; LHRH receptor agonists
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 May 2018 New trial record
    • 21 May 2018 Results presented at the 113th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top